



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

| | |
|---------------|----------------------------|
| Last Trade: | 33.36 |
| Trade Time: | 9:56 AM ET Feb 21, 2018 |
| Change: | 0.30 (+0.907%) |
| Day Range | 32.86 - 33.53 |
| 52-Week Range | 27.19 - 70.00 |
| Volume | 10,415 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 14, 2018

[Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update](#)

Feb 7, 2018

[Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference](#)

Feb 2, 2018

[Prothena Announces Departure of Chief Medical Officer](#)

Feb 1, 2018

[Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14](#)

Jan 3, 2018

[Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 27, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)